12.14 USD
▼-0.07-0.57%
盘后 12.71 +4.69%
2026-09-15
市值
$852.75M
市盈率
—
EPS
-0.83
股息率
—
52 周区间
1.94 – 15.10
成交量
1.05M
Beta
0.20
目标价
21.15
52W 低 1.9452W 高 15.10
价格走势
公司简介
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company’ lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.